Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.96 and traded as high as $3.77. Cortexyme shares last traded at $3.67, with a volume of 241,694 shares traded.
Cortexyme Stock Up 0.5%
The stock has a market cap of $110.65 million, a P/E ratio of -1.24 and a beta of 1.40. The business has a 50-day simple moving average of $2.58 and a 200-day simple moving average of $1.96.
About Cortexyme
Cortexyme, Inc is a clinical-stage biotechnology company focused on the development of treatments for Alzheimer’s disease and other chronic conditions associated with bacterial proteases. The company’s research centers on targeting virulence factors produced by the oral pathogen Porphyromonas gingivalis, an organism increasingly implicated in neurodegeneration. By inhibiting the activity of gingipains—proteolytic enzymes secreted by P. gingivalis—Cortexyme aims to reduce inflammation and tissue damage in the brain and other organs.
The company’s lead product candidate, atuzaginstat (COR388), is a small-molecule inhibitor designed to cross the blood–brain barrier and neutralize gingipain activity.
Featured Stories
- Five stocks we like better than Cortexyme
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Can Any Expenses Be Deducted From Capital Gains Tax?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Forget AI, This Will Be the Next Big Tech Breakthrough
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
